Freenome Achieves Landmark FDA Approval for SimpleScreen™ CRC Blood-Based Colorectal Cancer Screening Test; Abbott Secures Exclusive U.S. Commercialization Rights
Key Points for Investors
- FDA Approval: Freenome’s SimpleScreen™ CRC, a blood-based colorectal cancer (CRC) screening test, has received approval from the U.S. Food and Drug Administration for use in adults aged 45 and older at average risk.
- Exclusive U.S. Commercialization by Abbott: Abbott (NYSE: ABT) will exclusively commercialize the test in the U.S., with product launch expected in Fall 2026.
- Large Market Opportunity: The approval opens a significant market, addressing up to 60 million Americans overdue for CRC screening, with support from Medicare and expected inclusion in the American Cancer Society guidelines.
- Strong Clinical Validation: The test demonstrated 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia in the 48,000+ participant PREEMPT CRC study.
- Significant Milestone Payment: Freenome will receive a \$100 million milestone payment from Abbott for this FDA approval, under a commercial agreement signed in August 2025.
- Strategic Positioning and Platform Growth: This marks the first commercial product based on Freenome’s Personalized Cancer Detection strategy, with further expansion into multi-cancer testing anticipated.
Detailed Report
Freenome, Inc. (Nasdaq: FRNM), a leading innovator in early cancer detection, has secured a pivotal FDA approval for its SimpleScreen™ CRC test, a blood-based screening solution for colorectal cancer in adults 45 and older at average risk. The approval significantly enhances CRC screening options in the U.S., where an estimated 60 million eligible individuals remain unscreened for this preventable and treatable disease.
Through an exclusive agreement, Abbott (NYSE: ABT) will commercialize SimpleScreen CRC in the United States, leveraging its extensive provider relationships, reimbursement expertise, and patient support infrastructure developed through its Cologuard® platform. Abbott’s established Nexus platform will be instrumental in driving adoption and improving access to CRC screening across the healthcare system, with the commercial rollout scheduled for Fall 2026.
Clinical Validation & Performance
The FDA approval is backed by robust data from PREEMPT CRC, the largest prospective clinical validation study ever conducted for a blood-based colorectal cancer screening test. Over 48,000 asymptomatic, average-risk adults aged 45–85, scheduled for screening colonoscopy, participated across more than 200 sites.
Key results from the study include:
- 81.1% sensitivity for detecting colorectal cancer
- 13.7% sensitivity for advanced precancerous lesions (APLs), including 30.7% for APLs with high-grade dysplasia
- 90.4% specificity for advanced colorectal neoplasia
In practical terms, SimpleScreen CRC identified approximately 8 out of 10 colorectal cancers while producing negative results for 9 out of 10 people without CRC or advanced precancerous lesions.
Market Implications & Access
With FDA approval, SimpleScreen CRC qualifies for Medicare coverage and is expected to be specifically named in future American Cancer Society CRC screening guidelines. This positions the test for broad adoption and reimbursement, greatly expanding the addressable market.
As CRC is the second-leading cause of cancer death in the U.S., improved screening options are highly impactful. Experts, including Dr. Aasma Shaukat (NYU Grossman School of Medicine, PREEMPT CRC co-lead investigator), highlighted that a minimally invasive, blood-based test can significantly increase screening adherence among the unscreened eligible population, leading to earlier detection and improved outcomes.
Strategic and Financial Impact
Under the terms of the 2025 commercial agreement, Abbott will pay Freenome a \$100 million milestone payment upon FDA approval—a major revenue inflow for Freenome and a critical validation of its business model and clinical platform.
The approval marks the first commercial realization of Freenome’s Personalized Cancer Detection strategy, which utilizes cell-free DNA methylation analysis and AI/ML-driven accuracy. This technology platform will support a broader pipeline of single- and multi-cancer screening tests, positioning Freenome for future growth and expanded market share in the cancer diagnostics space.
Product Overview
SimpleScreen CRC is indicated for average-risk adults 45 and older, requiring only a simple blood draw. It detects CRC-associated signals from circulating cell-free DNA (cfDNA) in the blood. A positive result recommends follow-up by colonoscopy. Importantly, SimpleScreen CRC is not a replacement for diagnostic or surveillance colonoscopy in high-risk individuals.
Forward-Looking Considerations
The companies noted that forward-looking statements in their press release are subject to various risks, including competitive dynamics, regulatory timelines, the ability to scale and secure reimbursement, and potential changes in market adoption or healthcare policy. Investors should monitor subsequent SEC filings and company communications for updates on regulatory, commercial, and product development milestones.
Potential Price-Sensitive Factors for Shareholders
- FDA approval is a major value inflection point, validating Freenome’s platform and opening immediate market access.
- The \$100 million milestone payment from Abbott provides significant non-dilutive capital and de-risks near-term funding needs.
- Exclusive commercialization by Abbott leverages industry-leading infrastructure, increasing the likelihood of rapid provider and patient uptake.
- Inclusion in Medicare and ACS guidelines will likely drive reimbursement and adoption, enhancing revenue potential.
- Broader platform implications for multi-cancer screening could support future pipeline value and strategic partnerships.
About the Companies
- Freenome is focused on early cancer detection via blood-based screening, leveraging a proprietary multiomics discovery platform. The company is advancing tests for additional cancers, including lung, with a vision to increase screening participation across at-risk populations.
- Abbott is a global healthcare leader with businesses spanning diagnostics, medical devices, nutritionals, and branded generics, serving over 160 countries.
Contact Information
- Media (Freenome): Ryan Flinn, The Grace Group, [email protected], [email protected]
- Media (Abbott): Laura Anderson, [email protected]
- Investor Contact: [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.
